Ambeed.cn

首页 / / / Raf / Dabrafenib

达拉非尼 /Dabrafenib {[allProObj[0].p_purity_real_show]}

货号:A484347 同义名: 达拉菲尼 / GSK2118436A;GSK2118436

Dabrafenib (GSK2118436A) 是一种 ATP 竞争性的 Raf 抑制剂,对 C-RafB-RafV600E 的 IC50 值分别为 5 nM 和 0.6 nM。

Dabrafenib 化学结构 CAS号:1195765-45-7
Dabrafenib 化学结构
CAS号:1195765-45-7
Dabrafenib 3D分子结构
CAS号:1195765-45-7
Dabrafenib 化学结构 CAS号:1195765-45-7
Dabrafenib 3D分子结构 CAS号:1195765-45-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Dabrafenib 纯度/质量文件 产品仅供科研

货号:A484347 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 A-raf B-Raf C-Raf/Raf-1 Raf 其他靶点 纯度
Encorafenib 99%+
GDC-0879 ++++

B-Raf, IC50: 0.13 nM

99%+
SB-590885 ++++

B-Raf, Ki: 0.16 nM

99%+
RAF265 99%+
Dabrafenib ++++

B-Raf, IC50: 5.2 nM

B-Raf (V600E), IC50: 0.7 nM

+++

C-Raf, IC50: 6.3 nM

98%
Lifirafenib ++++

WT A-RAF, IC50: 1 nM

++

BRAF(V600E), IC50: 23 nM

BRAF WT, IC50: 32 nM

+++

C-RAF (Y340/341D), IC50: 7 nM

EGFR 98%
ZM 336372 +

C-Raf, IC50: 70 nM

99%+
NVP-BHG 712 +

C-Raf, IC50: 0.395 μM

99%+
CCT196969 +

BRAF, IC50: 0.1 μM

++

CRAF, IC50: 0.01 μM

Src 98%
Vemurafenib ++

B-Raf, IC50: 100 nM

B-Raf (V600E), IC50: 31 nM

+

C-Raf, IC50: 48 nM

98+%
PLX4720 ++

B-Raf, IC50: 160 nM

B-Raf (V600E), IC50: 13 nM

+++

C-Raf-1 (Y340D/Y341D), IC50: 6.7 nM

BRK 99+%
GW 5074 +++

C-Raf, IC50: 9 nM

99%+
Avutometinib +++

BRAF V600E, IC50: 8.2 nM

BRAF, IC50: 19 nM

+

CRAF, IC50: 56 nM

98%
LY3009120 ++++

BRAF(V600E), IC50: 5.8 nM

BRAF WT, IC50: 15 nM

++++

C-Raf, IC50: 4.3 nM

99%+
Agerafenib ++

B-Raf (V600E), Kd: 14 nM

B-Raf, Kd: 36 nM

+

C-Raf, Kd: 39 nM

RET 99%+
TAK-632 +++

B-Raf, IC50: 8.3 nM

++++

C-Raf, IC50: 1.4 nM

99%+
AZ 628 +

B-Raf, IC50: 105 nM

B-Raf (V600E), IC50: 34 nM

++

C-Raf-1, IC50: 29 nM

99%
PLX7904 98+%
Sorafenib ++

B-Raf (V599E), IC50: 38 nM

B-Raf, IC50: 22 nM

++++

Raf-1, IC50: 6 nM

++++

Raf-1, IC50: 6 nM

99%
Tovorafenib 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Dabrafenib 生物活性

靶点
  • B-Raf

    B-Raf, IC50:5.2 nM

    B-Raf (V600E), IC50:0.7 nM

  • C-Raf/Raf-1

    C-Raf, IC50:6.3 nM

描述 The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. Among them, B-RAF is the most frequently mutated protein kinase in human cancers. Dabrafenib is a potent, selective and efficacious inhibitor of B-RafV600E with IC50 value of 0.7 nM, and less potent to B-Raf and C-Raf with IC50 values of 5.2 nM and 6.3 nM (measured by enzymatic activity), respectively. Consistent with the in vitro kinase assay, Dabrafenib displayed compelling inhibitory on p-ERK in SKMEL28 cells with IC50 value of 4 nM, as well as on cell proliferation of B-RafV600E-driven melanoma lines such as SKMEL28 and A375P F11 (IC50=3 nM and 8 nM, respectively) and colorectal carcinoma line Colo205 (IC50=7 nM). Meanwhile, Dabrafenib had a minimal effect on cells with wild-type B-Raf (HFF IC50=3.0 μM) and in tumor cells not harboring the activating B-RafV600E mutation. Oral administration of Dabrafenib at doses of 0.1, 1, 10, and 100 mg/kg once daily for 14 days dose-dependently reduce tumor growth with notable pharmacodynamic response, measured by pERK levels after a single oral dose, in CD1 nu/nu mice bearing A375P F11 (B-RafV600E) tumors. Dabrafenib is currently in phase III clinical development for the treatment of activating B-Raf mutant tumors[1].
作用机制 Dabrafenib binding to BRAF is ATP-competitive.[2]

Dabrafenib 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
22Rv1 10 μM Growth Inhibition Assay 72 h IC50=10 μM 23844038
647-V 10 μM Growth Inhibition Assay 72 h IC50=10 μM 23844038
786-O 10 μM Growth Inhibition Assay 72 h IC50=10 μM 23844038
A101D 10 μM Growth Inhibition Assay 72 h IC50=9 nM 23844038

Dabrafenib 动物研究

Dose Mice: 0.3 mg/kg - 100 mg/kg[2] (p.o.) Dog: 1 mg/kg - 50 mg/kg[3] (p.o.) Rat: 5 mg/kg - 200 mg/kg[3] (p.o.)
Administration p.o.
Pharmacokinetics
Animal Rats[3]
Dose 20 mg/kg
Administration p.o.
Cmax 9.4 - 11.8 µg/ml
Tmax 0.5 - 1 h
AUC0→t 19.2 - 24.3 µg·h/ml

Dabrafenib 参考文献

[1]Rheault TR, Stellwagen JC, et al. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Med Chem Lett. 2013 Feb 7;4(3):358-62.

[2]King AJ, Arnone MR, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One. 2013 Jul 3;8(7):e67583.

[3]Tafinlar

Dabrafenib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.92mL

0.38mL

0.19mL

9.62mL

1.92mL

0.96mL

19.25mL

3.85mL

1.92mL

Dabrafenib 技术信息

CAS号1195765-45-7
分子式C23H20F3N5O2S2
分子量 519.562
别名 达拉菲尼 ;GSK2118436A;GSK2118436
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Room temperature

溶解度

DMSO: 35 mg/mL(67.36 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

2% DMSO+45% PEG 300+2% Tween 80+water 5 mg/mL

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。